What to expect in the first 48–72 hours

The hip joint will feel swollen and sore for a day or two after a ChondroFiller injection — that is entirely expected. Three predictable effects occur in the first 48–72 hours: localised swelling around the hip joint, a temporary pain flare, and stiffness that can make moving the leg feel effortful. These typically peak somewhere between 24 and 48 hours, then ease off.

The cause is mechanical and biological rather than harmful: placing a collagen gel inside the hip joint triggers a short-lived inflammatory response as the surrounding tissue begins to recognise and integrate the scaffold. This is the normal physiology of wound repair at work, not a sign that something has gone wrong.

This early period is uncomfortable for some patients, and there is no need to push through it unaided. Simple analgesics such as paracetamol are appropriate, gentle rest helps, and a cold pack wrapped in a cloth and applied to the outer hip can reduce swelling without interfering with the gel.

The normal trajectory is clear improvement within 72 hours. If swelling, pain, or stiffness persist beyond that point — or if any symptom is worsening rather than settling — contact the treating clinician for review. That threshold matters: persistence is the signal, not the discomfort itself.

Warning signs that need prompt attention

The normal pattern is discomfort that eases day by day; the pattern that needs attention is one that worsens, spreads, or becomes systemic.

Infection is the principal risk to watch for after any intra-articular hip injection — it is not unique to ChondroFiller, it is rare, but it needs to be caught early. Contact the treating clinician the same day if any of the following develop:

• Warmth around the hip joint that is noticeably increasing rather than settling
• Redness spreading beyond the injection site
• Pain that worsens significantly after the 72-hour mark instead of easing
• A fever, even a mild one

Any combination of these — particularly fever alongside escalating joint pain — warrants same-day or next-day clinical review. A joint infection identified promptly is manageable; one left untreated becomes considerably more serious.

Patients who have reached this point in their pathway will already have been assessed for anticoagulant use and other procedural risk factors — these are screened before the injection, not concerns to monitor at home afterwards.

Who is and is not a suitable candidate

Patient selection is, in many respects, the most important safety step of all — the procedure's strong record reflects the care taken to identify who will benefit before a single millilitre of gel is placed.

The most clinically significant limiter is the extent of hip joint degeneration. ChondroFiller is designed for focal cartilage defects — areas of full-thickness damage (Grade III or IV) surrounded by structurally sound cartilage. The 2021 hip cohort study published in the Journal of Hip Preservation Surgery found that patients with Tönnis grade 2–3 osteoarthritis, where the damage has spread diffusely across the joint, had poor results. The scaffold recruits cells from healthy surrounding tissue; if that tissue is itself worn away, the biological logic of the treatment breaks down. This distinction — focal versus diffuse — is the one that matters most when considering fit.

Two further absolute contraindications relate to the material itself. ChondroFiller is derived from murine (rat) Type I collagen, so a known allergy to murine proteins makes the injection unsafe regardless of defect size or location. This is straightforward to screen for in advance.

Active anticoagulation therapy is also an absolute contraindication, as is pregnancy — both are identified during the pre-procedure assessment and would preclude treatment until circumstances change.

Patients who fall into the right selection window — a focal acetabular cartilage lesion, often alongside femoroacetabular impingement, with no diffuse osteoarthritis — represent the group with the strongest published evidence behind them. Lincolnshire Hip's suitability assessment at lincolnshirehip.com/chondrofiller-suitability is a practical starting point for anyone wanting to check fit before booking a consultation.

Why activity matters while the gel integrates

Biomechanical in-vitro testing published in 2024 demonstrated that ChondroFiller cannot withstand full cyclic joint loading in the first hours after placement — at one and six hours post-application, the gel was still too unstable to protect opposing cartilage surfaces under impact. That finding has a direct practical implication: high-impact activity before stable scaffold integration risks physically displacing the gel from the defect. This is not a generic caution about soreness; it is a structural issue specific to ChondroFiller.

The distinction matters for how patients frame the restriction. Walking and gentle range-of-motion movement are generally encouraged — low-impact loading supports circulation and early healing without threatening scaffold stability. Running, jumping, and high-impact sport sit in a different category entirely and should be avoided until the treating clinician confirms that integration is sufficiently established to tolerate them.

The treating team will advise the specific timeline based on defect size and individual progress; no fixed number of weeks applies universally. The key point is that the restriction is time-limited, mechanically rational, and directly protective of the scaffold that has just been placed in the hip joint.

What the safety evidence actually shows

The global safety record for ChondroFiller is, by any reasonable measure, reassuring. Post-market surveillance by Meidrix Biomedicals GmbH, covering more than 19,000 cases performed since 2013, records zero serious adverse device effects and an overall complaint rate of approximately 0.06% — described as negligible in the Clinical Evaluation Report published in April 2025. A 2025 prospective clinical study found no significant difference in complications between ChondroFiller-treated patients and controls, providing independent corroboration of those figures.

The most directly applicable hip data comes from a 2021 prospective cohort published in the Journal of Hip Preservation Surgery. Twenty-six adults with femoroacetabular impingement and acetabular cartilage lesions exceeding 2 cm² were followed for three to five years; 17 of 21 evaluable patients achieved good or excellent results, with cartilage healing confirmed on MRI. Two subsequently required total hip replacement — a result the authors attribute to pre-existing joint degeneration rather than to treatment failure.

For wider procedural context, the reoperation rate for ChondroFiller injection is reported at 3–8%, against up to 41% for microfracture and up to 37% for ACI or MACI. Those comparisons are worth noting, but they should be read with care — the studies differ in design, patient population, and follow-up length, so they do not constitute head-to-head proof of superiority.

The honest limitation is straightforward: the evidence base is primarily manufacturer-sponsored post-market surveillance. Independent randomised controlled trials specifically in the hip joint are absent, and the hip-specific cohort of 26 patients is small. Larger randomised studies with long follow-up in hip populations remain the gap in the literature. That does not invalidate the existing data, but it is the context any patient should hold alongside the reassuring headline figures.

Accessing ChondroFiller at Lincolnshire Hip

ChondroFiller is delivered as an ultrasound-guided outpatient injection — no theatre admission, no general anaesthetic, no surgical incision. In the UK it is available only at private specialist centres; costs start from approximately £3,000 per unit, with the final figure depending on defect size and the volume of product required.

Lincolnshire Hip offers assessment and treatment at clinics in Sleaford and Grantham, drawing patients from across Lincolnshire and the wider non-London catchment. A suitability assessment confirms eligibility before any injection is offered.

For patients preparing for that appointment, the questions that follow naturally from everything covered in this article are the ones worth writing down: what grade and extent is the cartilage damage, are there signs of diffuse joint degeneration rather than a focal defect, and is any anticoagulant medication currently in use? Those clinical details — alongside any available MRI — are what allow a considered answer on whether ChondroFiller's safety profile is likely to translate to this particular hip. The evidence is reassuring, but it is only meaningful when the patient's anatomy and history have been weighed against it.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients for hip assessment without a GP referral.

1. [1] Arthroscopic utilisation of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Controlled, randomized multicenter study comparing ChondroFiller liquid with microfracturing for focal cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Utility of ultrasound-guided lateral hip injection using the short-axis image-parallel technique. (2025). https://doi.org/10.1093/jhps/hnaf069.128 https://doi.org/10.1093/jhps/hnaf069.128
4. [4] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
5. [5] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y